Atsuo Kuramasu
Overview
Explore the profile of Atsuo Kuramasu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
622
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amari Y, Hosonuma M, Mizukami T, Isobe J, Azetsu Y, Funayama E, et al.
Microbiol Spectr
. 2025 Jan;
13(2):e0169824.
PMID: 39817749
Importance: The gene polymorphism, which determines earwax characteristics, regulates the composition of the ear canal microbiota and its metabolic pathways. We determined the presence of genome-microbiome interactions in the resident...
2.
Funayama E, Hosonuma M, Tajima K, Isobe J, Baba Y, Murayama M, et al.
Biomed Pharmacother
. 2024 Dec;
182():117749.
PMID: 39719740
Gut bacteria play pivotal roles in the antitumor effects of immune checkpoint inhibitors (ICIs). However, antimicrobial therapy, often necessary for infections in cancer patients, can reduce the efficacy of ICIs....
3.
Toyoda H, Kuramasu A, Hosonuma M, Murayama M, Narikawa Y, Isobe J, et al.
Sci Rep
. 2024 Oct;
14(1):23401.
PMID: 39379424
Natural killer group 2 member D ligands (NKG2DLs) are expressed as stress response proteins in cancer cells. NKG2DLs induce immune cell activation or tumor escape responses, depending on their expression....
4.
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, et al.
Sci Rep
. 2024 May;
14(1):11325.
PMID: 38760458
The low response rate of immune checkpoint inhibitors (ICIs) is a challenge. The efficacy of ICIs is influenced by the tumour microenvironment, which is controlled by the gut microbiota. In...
5.
Otsuka K, Isobe J, Asai Y, Nakano T, Hattori K, Ariyoshi T, et al.
Cancer Immunol Immunother
. 2024 Jan;
73(2):23.
PMID: 38280026
Background: Recently, intestinal bacteria have attracted attention as factors affecting the prognosis of patients with cancer. However, the intestinal microbiome is composed of several hundred types of bacteria, necessitating the...
6.
Hosonuma M, Hirasawa Y, Kuramasu A, Murayama M, Narikawa Y, Toyoda H, et al.
Cancer Sci
. 2024 Jan;
115(3):752-762.
PMID: 38254257
Immune checkpoint inhibitor discovery represents a turning point in cancer treatment. However, the response rates of solid tumors remain ~10%-30%; consequently, prognostic and immune-related adverse event (irAE) predictors are being...
7.
Hamada K, Isobe J, Hattori K, Hosonuma M, Baba Y, Murayama M, et al.
Front Immunol
. 2023 May;
14:1164724.
PMID: 37207204
Introduction: Immune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly...
8.
Hamada K, Yoshimura K, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, et al.
Anticancer Res
. 2021 Oct;
41(10):4985-4993.
PMID: 34593446
Background/aim: There is an increasing use of immunotherapy for non-small cell lung cancer (NSCLC) patients. The present study analysed the effect of antibiotic use on the outcome of NSCLC patients...
9.
Honda T, Nishio Y, Sakai H, Asagiri M, Yoshimura K, Inui M, et al.
Cell Signal
. 2021 Mar;
83:109973.
PMID: 33689810
Histamine induces chemotaxis of mast cells through the histamine H receptor. This involves the activation of small GTPases, Rac1 and Rac2, downstream of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K). Activation of the H...
10.
Kuramasu A, Wakabayashi M, Inui M, Yanai K
J Pharmacol Exp Ther
. 2018 Jul;
367(1):9-19.
PMID: 30021868
Histamine induces chemotaxis of mast cells through the H receptor. However, little is known about the precise intracellular signaling pathway that mediates this process. In this study, we identified small...